Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenomic Strategies in Inflammatory Bowel Disease: Evaluating the Role of Pre-emptive HLADQA1 Genotyping for the Application of Targeted Infliximab-based Combination Therapy (INHERIT)

NCT04109300 is registered in ClinicalTrials.gov with Western University, Canada as lead sponsor.

NCT NCT04109300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04109300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenomic Strategies in Inflammatory Bowel Disease: Evaluating the Role of Pre-emptive HLADQA1 Genotyping for the Application of Targeted Infliximab-based Combination Therapy (INHERIT)
Lead sponsor
Western University, Canada
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2020
Completion date
September 1, 2023
Enrollment
162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, inflammatory bowel diseases, ulcerative colitis